Emergent BioSolutions Inc. has been awarded approximately $20 million to develop and manufacture an auto-injector containing diazepam (5 mg/mL) to treat nerve agent-induced seizures for the U.S. Department of Defense. Emergent’s device is being designed for intramuscular buddy-administration for use in military environments and for civilian emergencies. Under the multiple year agreement, awarded through the Medical CBRN Defense Consortium (MCDC), Emergent will develop a device, conduct studies to demonstrate consistent manufacturing, functionality, and usability of the final device, and complete regulatory activities required to obtain approval of the combination product by the U.S. Food and Drug Administration (FDA).
Read more about this news here.
